Form 4: Rhythm Pharmaceuticals Director Stuart Arbuckle Granted Stock Options and Restricted Stock Units

Rhythm Pharmaceuticals, Inc. Director Stuart A. Arbuckle was granted 7,037 stock options and 4,712 restricted stock units on June 24, 2025, as part of his compensation.

Summary

• Stuart A. Arbuckle, a Director of Rhythm Pharmaceuticals, Inc. (RYTM), acquired new derivative securities on June 24, 2025.
• He was granted 7,037 stock options with an exercise price of $63.66 per share.
• He also received 4,712 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Issuer common stock.
• Both the stock options and RSUs will fully vest upon the earlier of June 24, 2026, or the day immediately prior to the Issuer's next annual meeting of stockholders to be held in 2026, subject to his continued service.
• The stock options have an expiration date of June 23, 2035.
• The restricted stock units have no expiration date.

Sentiment

Score: 7

Explanation: The document reports a routine equity grant to a director, which is a positive for aligning interests but does not indicate significant new positive or negative operational news. It's a standard compensation event.

Positives

• The grant of stock options and restricted stock units to a director indicates continued alignment of management incentives with shareholder interests.
• The vesting schedule encourages long-term commitment and continued service from the director.

Negatives

• No immediate cash transaction or direct share purchase by the director, which might signal stronger conviction.

Risks

• The value of the stock options and RSUs is dependent on the future performance of Rhythm Pharmaceuticals' stock price.
• Vesting of the equity awards is subject to the director's continued service with the company.

Future Outlook

The grants of equity compensation are forward-looking, aligning the director's incentives with the company's long-term stock performance and continued service.

Industry Context

Equity grants to directors are a standard practice in the biotechnology and pharmaceutical industries to attract and retain talent, aligning their interests with long-term company growth and shareholder value creation. This is a routine compensation event.

Comparison to Industry Standards

• The grant of stock options and restricted stock units to a director is a common form of equity compensation across the pharmaceutical and biotechnology sectors.
• While specific grant sizes and vesting schedules vary by company and individual role, this type of incentive aligns director interests with shareholder value, similar to practices at companies like Vertex Pharmaceuticals (VRTX) or Regeneron Pharmaceuticals (REGN) which also utilize equity-based compensation for their board members to encourage long-term commitment and performance.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholder value creation, as the value of the equity compensation is tied to the company's stock performance.

Next Steps

• The stock options and RSUs will vest on the earlier of June 24, 2026, or the day prior to the 2026 annual meeting, subject to continued service.
• The director will continue to serve on the board of Rhythm Pharmaceuticals, Inc.

Key Dates

Recommendation

Keywords

Rhythm Pharmaceuticals, RYTM, SEC Form 4, Insider Transaction, Stock Options, Restricted Stock Units, Director Compensation, Equity Grant, Stuart A. Arbuckle, Biotechnology, Pharmaceuticals